SCHEMBL114867

SCHEMBL114867

O=C(Cl)c1cc(F)cc(F)c1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CES2 O00748 6/20 0.62
CES1 P23141 6/20 0.62
HCAR1 Q9BXC0 1/20 0.44
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA9 Q16790 1/20 0.41
SLC6A3 Q01959 1/20 0.39
HCAR2 Q8TDS4 1/20 0.38
PARP1 P09874 1/20 0.38
TTR P02766 1/20 0.36
ALDH1A1 P00352 1/20 0.36
ALOX15 P16050 1/20 0.36
HDAC1 Q13547 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GRM5 P41594 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2293145 0.94 CES2 (0.55) CES2CES1HCAR1CA12CA1
SCHEMBL5223999 0.85 CES2 (0.46) CES2CES1HCAR1GRM5
SCHEMBL29558481 0.85 CES2 (0.46) CES2CES1HCAR1GRM5
SCHEMBL5225361 0.84 CES2 (0.44) CES2CES1HCAR1SLC6A3HCAR2
SCHEMBL15935951 0.84 CES2 (0.44) CES2CES1HCAR1SLC6A3HCAR2
SCHEMBL31327392 0.84 CES2 (0.44) CES2CES1HCAR1SLC6A3HCAR2
SCHEMBL679313 0.80 CES2 (0.52) CES2CES1HDAC1HDAC6
SCHEMBL29593993 0.80 CES2 (0.52) CES2CES1HDAC1HDAC6
SCHEMBL3612973 0.79 NPC1 (0.45) CES2CES1PARP1ALDH1A1NPC1
SCHEMBL5222697 0.79 CES2 (0.45) CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 852 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250297056-A1 METHOD FOR PRODUCING POLYETHERKETONEKETONE ARKEMA FRANCE (FR) 2025-09-25 US claimed
EP-4519341-A1 METHOD FOR PRODUCING POLYETHERKETONEKETONE ARKEMA FRANCE (FR) 2025-03-12 EP claimed
CN-119487101-A Method for producing polyetherketoneketone 阿科玛法国公司 2025-02-18 CN claimed
WO-2024250573-A1 REVERSE OSMOSIS MEMBRANE PREPARATION METHOD AND REVERSE OSMOSIS MEMBRANE PREPARED THEREBY 沃顿科技股份有限公司 2024-12-12 WO claimed
CN-119098067-A Method for producing reverse osmosis membrane and reverse osmosis membrane produced thereby 沃顿科技股份有限公司 2024-12-10 CN claimed
CN-118994606-A Lithium battery negative electrode binder and preparation method and application thereof 艾迪天目(常州)新材料科技有限公司 2024-11-22 CN claimed
CN-117123191-A For CO 2 Adsorbed resin and preparation method thereof 中国科学院广州能源研究所 2023-11-28 CN claimed
CN-117105897-A HNO donor compound and preparation method thereof 海南大学 2023-11-24 CN claimed
CN-117105826-A HNO-releasable compound and preparation method thereof 海南大学 2023-11-24 CN claimed
WO-2023214052-A1 METHOD FOR PRODUCING POLYETHERKETONEKETONE ARKEMA FRANCE (FR) 2023-11-09 WO claimed
CN-113773264-A Pyrimidine amide compound applied to herbicide and preparation method thereof 池州飞昊达化工有限公司 2021-12-10 CN claimed
CN-103487455-B A kind of method of hydroxy-containing compounds in Quantitative detection olive oil SHANGHAI UNIVERSITY (CN) 2016-04-27 CN claimed
CN-103487455-A Novel method for quick quantitative determination of hydroxy components in olive oil UNIV SHANGHAI 2014-01-01 CN claimed
CN-1785993-B Preparation and use of non-natural isocoumarin derivatives UNIV NANKAI 2012-03-14 CN claimed
US-6803484-B2 Sulfonamide derivatives ELI LILLY AND COMPANY 2004-10-12 US claimed
US-20040143020-A1 Sulfonamide derivatives AIKINS JAMES ABRAHAM (US) 2004-07-22 US claimed
US-6720357-B2 TREATMENT OF CONDITIONS ASSOCIATED WITH GLUTAMATE HYPOFUNCTION, SUCH AS PSYCHIATRIC AND NEUROLOGICAL DISORDERS; N-2-(4-N-(3,5-DIFLUOROBENZAMIDO)PHENYL)PROPYL-2-PROPANESULFONAMIDE ELI LILLY AND COMPANY 2004-04-13 US claimed
US-20030233015-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-18 US claimed
EP-1296944-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-04-02 EP claimed
WO-2001090056-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-11-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030233015-A1 Sulfonamide derivatives GRIN2A, GRIN1, SLC1A2 CES2 532/4885CES1 1233/4885HCAR1 855/4885
US-20040143020-A1 Sulfonamide derivatives GRIN2A, GRIN2B, SLC1A2 CES2 510/4885CES1 1912/4885HCAR1 1019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.